StreetInsider.com News Articles

Polaryx Therapeutics Deepens Engagement with the Krabbe Disease Community Through Scientific and Patient Advocacy Events

Thu, 12 Mar 2026 08:30:00 -0400

PARAMUS, NJ, March 12, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”), announces its participation in two upcoming events supporting the Krabbe disease community. These events reflect Polaryx’s ongoing commitment to advancing research and strengthening engagement with patients, caregivers, and clinicians.

2026 Krabbe Translational Research Network

Members of the Polaryx executive team, including Dr. Lisa Bollinger, Chief Medical Officer, Dr. Shrijay Vijayan, Chief Scientific and Business Development Officer, and Dr. Minsu Kang, Director of Regulatory and Clinical Affairs, will attend

Polaryx Therapeutics Deepens Engagement with the Krabbe Disease Community Through Scientific and Patient Advocacy Events

Thu, 12 Mar 2026 08:30:00 -0400

2026 Krabbe Translational Research Network

Polaryx Therapeutics Marks Rare Disease Day, Reaffirming Commitment to Patients with Rare Pediatric Lysosomal Storage Disorders

Fri, 27 Feb 2026 08:30:00 -0400

PARAMUS, NJ, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”), joins the global rare disease community in raising awareness and supporting patients, families, caregivers, and healthcare providers.

“On Rare Disease Day, Polaryx proudly stands alongside the rare disease community - patients, families, caregivers, researchers, and advocacy partners to underscore the urgent need for new and transformative treatments,” said Alex Yang, Chairman and Chief Executive Officer of Polaryx Therapeutics, Inc. “We are deeply committed to raising awareness of rare pediatric lysosomal

Polaryx Therapeutics Marks Rare Disease Day, Reaffirming Commitment to Patients with Rare Pediatric Lysosomal Storage Disorders

Fri, 27 Feb 2026 08:30:00 -0400

Maxim Group Starts Polaryx Therapeutics (PLYX) at Buy

Fri, 27 Feb 2026 07:41:32 -0400

Maxim Group analyst Jason McCarthy initiates coverage on Polaryx Therapeutics (NASDAQ: PLYX) with a Buy rating and a price target of $10.00.

For an analyst ratings summary and ratings history on click here. For more ratings news on click here.

Shares of closed at $3.19 yesterday.

Form 4 Polaryx Therapeutics, For: Feb 18 Filed by: Landis G. Michael

Fri, 20 Feb 2026 16:42:00 -0400

si-local-file:///var/storage/secattach/20260220/26036764.html

Polaryx selects CRO partner for phase 2 trial of rare disease drug

Tue, 17 Feb 2026 08:30:21 -0400

Polaryx Therapeutics Inc. (NASDAQ: PLYX) announced it has selected a contract research organization to conduct SOTERIA, a phase 2 trial evaluating its lead drug candidate PLX-200 for four rare pediatric lysosomal storage disorders.

The open-label, single-arm trial will assess the safety, tolerability, and clinical activity of PLX-200 in patients with CLN2, CLN3, Krabbe disease, and Sandhoff disease. The company received FDA clearance to proceed with the trial in October 2025 and plans to initiate the study in the first half of 2026.

PLX-200 is an oral formulation of gemfibrozil, an FDA-approved lipid-regulating agent. The compound can cross the blood-brain barrier, according to

Polaryx Therapeutics Selects Contract Research Organization for SOTERIA Phase 2 Basket Trial

Tue, 17 Feb 2026 08:30:00 -0400

PARAMUS, NJ, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”), announces it has selected a leading contract research organization (CRO) for SOTERIA, a phase 2, open-label, single-arm trial designed to evaluate the safety, tolerability, and clinical activity of Polaryx’s lead candidate, PLX-200, across four different LSDs.

“Our selection of a CRO partner marks an important milestone for us as we continue to advance the clinical development of SOTERIA and move closer to the clinic,” said Lisa Bollinger, M.D., Chief

Polaryx Therapeutics Selects Contract Research Organization for SOTERIA Phase 2 Basket Trial

Tue, 17 Feb 2026 08:30:00 -0400

“Our selection of a CRO partner marks an important milestone for us as we continue to advance the clinical development of SOTERIA and move closer to the clinic,” said Lisa Bollinger, M.D., Chief

Polaryx shares preclinical data for Krabbe disease treatment PLX-200

Tue, 10 Feb 2026 08:32:34 -0400

Polaryx Therapeutics (NASDAQ: PLYX) presented preclinical data for its investigational treatment PLX-200 at the 22nd Annual WORLDSymposium on February 6 in San Diego. The data focused on PLX-200's effects on Krabbe disease, one of four lysosomal storage disorders included in the company's upcoming Phase 2 SOTERIA basket trial.

The preclinical study used a mouse model of Krabbe disease and showed that orally administered gemfibrozil, the active component of PLX-200, reduced astrogliosis and neuroinflammation, protected myelin, and reduced accumulation of psychosine, a toxic metabolite associated with Krabbe disease. The treatment also restored motor functions and increased lifespan in the mouse model.

Chief Scientific

Polaryx shares preclinical data for Krabbe disease treatment PLX-200

Tue, 10 Feb 2026 08:32:34 -0400

Chief Scientific

Polaryx Announces Key Pre-Clinical Data Related to SOTERIA at the 22nd Annual WORLDSymposium™

Tue, 10 Feb 2026 08:30:00 -0400

Oral presentation highlighted the effect of gemfibrozil on Krabbe disease, one of four LSDs in the upcoming Phase 2 SOTERIA basket trial evaluating PLX-200 (reformulated gemfibrozil)

PARAMUS, NJ, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”), announced that the late-breaking presentation of new data for PLX-200, an investigational therapy for the treatment of Krabbe disease (globoid cell leukodystrophy) at the 22nd Annual WORLDSymposium™, was given on February 6, 2026 in San Diego, Calif.

Key Findings and Scientific Perspective

At the

Polaryx Announces Key Pre-Clinical Data Related to SOTERIA at the 22nd Annual WORLDSymposium™

Tue, 10 Feb 2026 08:30:00 -0400

Oral presentation highlighted the effect of gemfibrozil on Krabbe disease, one of four LSDs in the upcoming Phase 2 SOTERIA basket trial evaluating PLX-200 (reformulated gemfibrozil)

Key Findings and Scientific Perspective

At the

Form SCHEDULE 13D Polaryx Therapeutics, Filed by: Mstone Partners Healthcare Ltd

Thu, 05 Feb 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260205/25954759.html

Polaryx to Present Late-Breaker Data Related to SOTERIA at the 22nd Annual WORLDSymposium™ as Company Prepares for SOTERIA Trial Launch

Tue, 03 Feb 2026 08:30:00 -0400

Oral presentation provides additional scientific rationale on Krabbe disease, one of four LSDs in the Phase 2 SOTERIA basket trial designed to evaluate the safety and clinical activity of lead drug candidate PLX-200

PARAMUS, NJ, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”), announces it will be presenting a late-breaking abstract on new data for PLX-200, an investigational therapy for the treatment of Krabbe disease (globoid cell leukodystrophy) at the 22nd Annual WORLDSymposium™, held February 2-6, 2026 in San Diego, Calif. These

Polaryx to Present Late-Breaker Data Related to SOTERIA at the 22nd Annual WORLDSymposium™ as Company Prepares for SOTERIA Trial Launch

Tue, 03 Feb 2026 08:30:00 -0400

Form 424B4 Polaryx Therapeutics,

Mon, 02 Feb 2026 16:06:00 -0400

http://archive.fast-edgar.com/20260202/AL22W62CLC22BZ8222292ZY2OPPQC2224282

Filed on: February 2, 2026